Changes in plasma IL-6, plasma VEGF and serum YKL-40 during Treatment with Etanercept and Methotrexate or Etanercept alone in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy
- PMID: 20029652
- PMCID: PMC2796864
- DOI: 10.4137/bmi.s2300
Changes in plasma IL-6, plasma VEGF and serum YKL-40 during Treatment with Etanercept and Methotrexate or Etanercept alone in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy
Abstract
Changes in plasma IL-6, plasma VEGF and serum YKL-40 were determined in rheumatoid arthritis (RA) patients during treatment with etanercept alone or in combination with methotrexate. Twenty-five patients with active RA (DAS28 >/= 3.2) were randomized to receive etanercept (25 mg sc. biweekly) plus methotrexate (n = 12) or etanercept alone (n = 13). Plasma IL-6, plasma VEGF and serum YKL-40 were determined by ELISA. The 3 biomarkers and DAS28 scores were evaluated at baseline and after 4, 8, 12 and 16 weeks of treatment. At inclusion all patients had significantly (p < 0.001) elevated plasma IL-6, plasma VEGF and serum YKL-40 compared to healthy subjects. Eighteen patients responded to treatment (pooled data from both treatment groups), and they had significant (p < 0.05 to p < 0.001) decreases in plasma IL-6, plasma VEGF, serum YKL-40, ESR and DAS28 after 4 weeks of treatment and throughout the study (except serum YKL-40 at week 16). Plasma IL-6 showed the largest reductions. Non-responders had unchanged biomarkers. At week 16 the patients with DAS28 < 3.2 had lower levels compared to baseline values in plasma IL-6 (p = 0.005), plasma VEGF (p = 0.014), and ESR (p = 0.024).Plasma IL-6, plasma VEGF and serum YKL-40, which reflect different aspects of the inflammatory process, may provide useful information regarding early differentiation of responders from non-responders.
Keywords: IL-6; VEGF; YKL-40; biomarkers; etanercept; rheumatoid arthritis.
Figures

Similar articles
-
Circulating serum interleukin-6, serum chitinase-3-like protein-1, and plasma vascular endothelial growth factor are not predictive for remission and radiographic progression in patients with early rheumatoid arthritis: post-hoc explorative and validation studies based on the CIMESTRA and OPERA trials.Scand J Rheumatol. 2018 Jul;47(4):259-269. doi: 10.1080/03009742.2017.1376107. Epub 2018 Jan 16. Scand J Rheumatol. 2018. PMID: 29336711
-
Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access.Rheumatol Int. 2017 Sep;37(9):1469-1479. doi: 10.1007/s00296-017-3749-7. Epub 2017 Jun 9. Rheumatol Int. 2017. PMID: 28597306 Clinical Trial.
-
When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: findings from a randomized study (COMET).J Rheumatol. 2014 Oct;41(10):1922-34. doi: 10.3899/jrheum.131238. Epub 2014 Aug 15. J Rheumatol. 2014. PMID: 25128520 Clinical Trial.
-
Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial.Arthritis Res Ther. 2018 Jan 16;20(1):8. doi: 10.1186/s13075-017-1484-9. Arthritis Res Ther. 2018. PMID: 29338762 Free PMC article. Clinical Trial.
-
Etanercept: a review of its use in rheumatoid arthritis.Drugs. 1999 Jun;57(6):945-66. doi: 10.2165/00003495-199957060-00014. Drugs. 1999. PMID: 10400407 Review.
Cited by
-
Tofacitinib treatment modulates the levels of several inflammation-related plasma proteins in rheumatoid arthritis and baseline levels of soluble biomarkers associate with the treatment response.Clin Exp Immunol. 2022 Dec 15;210(2):141-150. doi: 10.1093/cei/uxac085. Clin Exp Immunol. 2022. PMID: 36124688 Free PMC article.
-
The role of YKL-40 in the pathogenesis of autoimmune diseases: a comprehensive review.Int J Biol Sci. 2022 May 21;18(9):3731-3746. doi: 10.7150/ijbs.67587. eCollection 2022. Int J Biol Sci. 2022. PMID: 35813465 Free PMC article. Review.
-
Patients with the most advanced rheumatoid arthritis remain with Th1 systemic defects after TNF inhibitors treatment despite clinical improvement.Rheumatol Int. 2014 Feb;34(2):243-53. doi: 10.1007/s00296-013-2895-9. Epub 2013 Nov 13. Rheumatol Int. 2014. PMID: 24221190 Free PMC article.
-
VEGFR2 promotes central endothelial activation and the spread of pain in inflammatory arthritis.Brain Behav Immun. 2018 Nov;74:49-67. doi: 10.1016/j.bbi.2018.03.012. Epub 2018 Mar 14. Brain Behav Immun. 2018. PMID: 29548992 Free PMC article.
-
Relationship between sonographic parameters and YKL-40 levels in rheumatoid arthritis.Rheumatol Int. 2013 Feb;33(2):341-6. doi: 10.1007/s00296-012-2387-3. Epub 2012 Mar 27. Rheumatol Int. 2013. PMID: 22451025
References
-
- Klareskog L, Van der Heijde D, de Jager JP. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet. 2004;363:675–681. - PubMed
-
- Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev. 2002;13:357–368. - PubMed
-
- Ikeda M, Hosoda Y, Hirose S, et al. Expression of vascular endothelial growth factor isoforms and their receptors Flt-1, KDR and neuropilin-1 in synovial tissue of rheumatoid arthritis. J Pathol. 2001;191:426–433. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous